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Introduction. Cytophagic histolytic panniculitis (CHP) is a clinical disorder characterized by nodular panniculitis of the
subcutaneous adipose tissue. It was first described in 1980 by Winkelmann. Histologically it is described as an infiltration of the
adipose tissue byT- lymphocytes andphagocyticmacrophages (also known as “bean bag cells”).Most of the cases are reported under
the age of 50 and is a rare cause of panniculitis. We report a case of CHP in a young patient who presented to our emergency room
(ER). Case Summary. A 39-year-old African American woman who presented to our hospital with lethargy, progressive confusion,
and generalized rash involving both lower extremities of 1 week duration. She had a history of pancytopenia and focal proliferative
and membranous lupus nephritis classes 3 and 5. Her physical examination was remarkable for bilateral lower extremity pitting
edema and a desquamating rash on both of her legs.TheNicolsky signwas positive. She was noted to be hypotensive andwas started
on intravenous fluids and broad spectrum antibiotics. Routine laboratory tests revealed severe pancytopenia, with a hemoglobin of
3.9 g/dl, white blood cell count 600/ul, and platelet count of 11000/ul. Within an hour of arrival to the ER she developed acute
respiratory failure. She was intubated and placed on mechanical ventilation. She developed shock requiring vasopressors. No
imaging could be done due to her unstable condition. Four hours after her initial presentation she developed asystole and expired.
Postmortem histopathology of the adipose tissue revealed CHP. Conclusion. CHP can be rapidly fatal. The treatment involves high
dose of intravenous steroids and immunosuppressants such as cyclosporine.
1. Introduction
Cytophagic histiocytic panniculitis (CHP) is a rare clinical
disorder, characterized by nodular panniculitis of the subcu-
taneous adipose tissue [1]. It was first described in 1980 by
Winkelmann, as an infiltration of the subcutaneous adipose
tissue by T lymphocytes and phagocytic histiocytes (also
known as the “bean bag cells”) [2]. It is a rare cause of aseptic
panniculitis [2–4] that is seen in association with viral infec-
tions (HSV, EBV) [5], hematopoietic disorders (malignant
lymphoma), hemophagocytic lymphohistiocytosis (HLH),
acute leukemias (acute lymphoid leukemia, acute myeloid
leukemia), Hodgkin’s and non-Hodgkin’s lymphoma, rhab-
domyosarcoma, neuroblastoma, and Langerhans cell histi-
ocytosis [6, 7]. Reports of CHP after H1N1 vaccination are
available in the literature [8]. Its associationwith autoimmune
diseases like systemic lupus erythematosus (SLE) is also
reported and has a high mortality rate [9–12]. However, only
a few such cases confirming the association between SLE and
CHP are available. We report one such case of CHP in a
patient with SLE that ultimately resulted in the demise of the
patient.
2. Case Report
A 39-year-old African American woman was brought to our
emergency room (ER) with lethargy, progressive confusion,
and generalized rash involving both lower extremities of 1-
week duration. Two months ago, the patient had presented
Hindawi
Case Reports in Dermatological Medicine
Volume 2019, Article ID 6830862, 4 pages
https://doi.org/10.1155/2019/6830862
2 Case Reports in Dermatological Medicine
Figure 1: Rash on the back with bullae, rash on the posterior aspect of legs, and desquamating rash on the back.
to our hospital with left lower quadrant pain and nonbloody
diarrhea and dizziness. A Computed Tomography (CT) of
the abdomen and pelvis had revealed pancolitis and she was
treated with antibiotics. At that time she was also found to
have proteinuria, pedal edema and photosensitive rash on
her face.The proteinuria was attributed to glomerular disease
of unclear etiology. Autoimmune work-up revealed positive
ANA, anti-Smith Ab, and anti-RNP. Parvovirus IgG was also
positive. Shewas found to have pancytopenia and the diagno-
sis of aplastic anemia was considered and she was transferred
to another tertiary care hospital.There, she underwent a renal
biopsy that revealed focal proliferative and membranous
lupus nephritis classes 3 and 5. She was discharged on
prednisone, mycophenolate, and hydroxychloroquine. Now
she had presented with the current complains.
In the ER she was found to be lethargic. On physical
examination, her temperature was 97.5∘F, pulse was 102 beats
per minute, the initial blood pressure was 136/79 mm of
Hg, and respiratory rate was 22 breaths per minute. There
was no scleral icterus. Oral mucosa was dry without visible
lesions. The neck was supple. Skin was warm and had
desquamating rash on both lower extremities from hip down
(Figure 1). The rash was nonblanching and erythematous,
and Nicolsky sign was positive. The abdomen was soft
but mild tenderness was noted in the epigastric region
without any guarding or rebound tenderness. There was no
organomegaly and the bowel soundswere sluggish.Therewas
bilateral pitting pedal edema. The patient was arousable with
verbal and tactile stimulation and was moving all extrem-
ities spontaneously. Rest of the physical examination was
unremarkable.
Later she developed hypotension and was given on
intravenous fluids. Sepsis was suspected and broad spectrum
antibiotics were initiated. The early differential diagnosis
included Steven Johnson syndrome vs. necrotizing fasciitis
causing sepsis. Her labs revealed severe pancytopenia and
severe metabolic acidosis. Detailed results of the laboratory
parameters are given in Table 1.
She was transfused 2 units of packed red blood cells
and 6 units of platelets. Within an hour of arrival to
the ER she developed acute respiratory failure and was
intubated and placed on mechanical ventilation. She devel-
oped septic shock requiring vasopressors. She was deemed
Table 1: Initial laboratory workup.
Parameter Initial laboratory results Reference range
Hemoglobin
(g/dl) 3.9 12-16
White blood cell
count (per
mm3)
0.6 4.8-10.8
Platelet count
(k/ul) 11 150-400
Sodium
(mEq/L) 129 135-145
Potassium
(mEq/L) 7.1 3.5-5.0
HCO3 (mEq/L) 11 24-30
Ph 6.9 7.35-7.45
BUN (mg/dl) 52 6- 20
Creatinine
(mg/dl) 3 0.5 -1.5
Glucose (mg/dl) 376 70-120
Lactic acid
(mmoles/L) 6.7 0.5-1.6
AST (mg/dl) 50 9-48
ALT (mg/dl) 20 5 -40
Total
bilirubin/direct
(mg/dl)
0.2 0.2-1.2
Alkaline
phosphatase
U/L
20 53-141
Albumin (g/dl) 0.4 3.2-4.8
Urine
toxicology
screen
negative negative
Blood culture Serratia marcescenspositive negative
too unstable for imaging studies but a portable chest X-
ray revealed right basilar atelectasis and portable X-ray
of the lower extremities showed soft tissue edema. Four
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Figure 2: (a)The arrows indicate macrophages engulfingmostly the red blood cells (bean bag cells), (b) this is lobular panniculitis comprised
of cellular infiltrate of lymphocytes, macrophages, and plasma cells, (c) septal panniculitis (highlighted), and (d) subepidermal bullous lesion.
hours after the initial presentation she developed asystole
and expired after failed resuscitative measures. An autopsy
was done that revealed CHP (Figure 2), Libman Sacks
endocarditis, bilateral pleural effusion, proliferative and
membranous lupus glomerular nephropathy, and bilateral
adrenal hemorrhage. Blood culture postmortemgrew serratia
marcescens.
3. Discussion
CHP has an elaborate spectrum of clinical presentations. It
can present with a wide array of symptoms ranging from
local skin lesions to a life threatening systemic illness as
associated with hemophagocytic syndrome (HLH) [12]. It
can present with recurrent fever, subcutaneous nodules,
hepatosplenomegaly, abnormal liver function tests, pancy-
topenia, polyserositis, and hemorrhagic diathesis [2, 13].
Its clinical course is variable depends on degree of sever-
ity. Some patients developed chronicity having recurring
bouts over the course of their illness and surviving for years
[14–16]. In others, it can rapidly progress resulting in the
demise of the patients from sepsis and multiorgan failure
[2, 13, 17]. Diagnosis is particularly challenging as it is a
rare disorder and limited literature is available for guiding
the management of this disease. The differential diagnosis is
wide, including tuberculosis and histiocytosis. The diagnosis
requires a skin biopsy, which shows characteristic histologic
findings; “bean bag cells” are pathognomonic.
The current treatment options include high dose of
steroids and immunosuppressants such as cyclosporine A as
the first line agents [9, 18]. Recently other treatment modal-
ities like chemotherapy have also been used successfully,
CHOP (cyclophosphamide, doxorubicin, vincristine, and
prednisolone) being the most commonly used chemotherapy
regimen. In treatment refractory cases the use of azathio-
prine, cyclophosphamide, tacrolimus, plasmapheresis, and
autologous peripheral blood stem cell transplantation has
also been reported [19].
CHP has a poor prognosis and a highmortality up to 70%
in severe cases, while other cases are successfully treated with
immunosuppressive agents like cyclosporine [9, 15, 18, 19].
CHP in patients with SLE is a rare combination and to date
only a handful such cases have been reported in medical
literature. Fever, lymphadenopathy, and pancytopenia are
some of the clinical features that indicate poor prognosis
in such patients [9]. Our patient had pancytopenia and
had a rapidly progressive decline in clinical picture that is
characteristic of this disorder in severe cases as mentioned
earlier. Unfortunately our patient expired in a very short
period of presentation to the ER and diagnosis was made
postmortem with autopsy. Clinicians should be aware of this
uncommon disorder as the delay in treatment can be rapidly
fatal.
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